Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지
DOI QR코드

DOI QR Code

A rare case of osteonecrosis of the jaw related to imatinib

  • Viviano, Massimo (Department of Medical Biotechnologies (Dentistry), University of Siena) ;
  • Rossi, Marco (Department of Medicine, Surgery and Neuroscience (Pharmacology), University of Siena) ;
  • Cocca, Serena (Department of Medicine, Surgery and Neuroscience (ENT), University of Siena)
  • Received : 2016.05.23
  • Accepted : 2016.08.13
  • Published : 2017.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Osteonecrosis of the jaw (ONJ) is commonly described as an adverse effect of the use of bisphosphonates. A few cases of ONJ associated with tyrosine kinase inhibitors (sunitinib, imatinib) have been reported in the literature and usually they occurred in patients simultaneously treated with bisphosphonates. We report an atypical case of ONJ related only to imatinib. A 72-year-old male patient was treated with imatinib for metastases from gastrointestinal stromal tumors (GISTs). The patient developed ONJ after 22 months of imatinib only therapy. During his whole life, the patient had never been treated with bisphosphonates or radiotherapy. Microscope examination of the tissues confirmed the clinical diagnosis of diffuse osteonecrosis and showed absence of neoplastic cells. Thus, secondary localisations from GISTs were ruled out. Osteonecrosis of the lower jaw appeared 22 months after initial and exclusive therapy with imatinib. Therefore, imatinib monotherapy can induce ONJ in patients that have never been treated with bisphosphonates or radiotherapy.

Keywords

References

  1. Dulucq S, Krajinovic M. The pharmacogenetics of imanitib. Genome Med 2010;2:85. https://doi.org/10.1186/gm206
  2. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72:1938-56. https://doi.org/10.1016/j.joms.2014.04.031
  3. Lutz JC, El-Bouihi M, Vidal N, Fricain JC, Robert M, Deminiere C, et al. Mandibular metastases from an ileum stromal tumor. Rev Stomatol Chir Maxillofac 2008;109:399-402. https://doi.org/10.1016/j.stomax.2008.09.010
  4. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6. https://doi.org/10.1056/NEJM200104053441404
  5. Yeh CN, Fu CJ, Yen TC, Chiang KC, Jan YY, Chen MF. Osteonecrosis of the tibia associated with imatinib in metastatic GI stromal tumor. J Clin Oncol 2013;31:e248-50. https://doi.org/10.1200/JCO.2012.45.1294
  6. Nicolatou-Galitis O, Razis E, Galiti D, Vardas E, Tzerbos F, Labropoulos S. Osteonecrosis of the jaw in a patient with chronic myelogenous leukemia receiving imatinib. A case report with clinical implications. Forum Clin Oncol 2013;4:29-33.
  7. Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, et al. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer 2012;107:1665-71. https://doi.org/10.1038/bjc.2012.385
  8. Fleissig Y, Regev E, Lehman H. Sunitinib related osteonecrosis of jaw: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol 2012;113:e1-3. https://doi.org/10.1016/S2212-4403(11)00652-3
  9. Abramson RG, Abramson VG, Chan E, Horn L, Keedy VL, Pao W, et al. Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. AJR Am J Roentgenol 2013;200:475-83. https://doi.org/10.2214/AJR.12.9049
  10. Vlahovic G, Rabbani ZN, Herndon JE 2nd, Dewhirst MW, Vujaskovic Z. Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. Br J Cancer 2006;95:1013-9. https://doi.org/10.1038/sj.bjc.6603366
  11. Litz J, Krystal GW. Imatinib inhibits c-Kit-induced hypoxiainducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells. Mol Cancer Ther 2006;5:1415-22.
  12. Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino AC. Dysregulation of bone remodeling by imatinib mesylate. Blood 2010;115:766-74. https://doi.org/10.1182/blood-2009-08-237404

Cited by

  1. Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naïve Patient: A Comprehensive Review of the Literature vol.2018, pp.None, 2017, https://doi.org/10.1155/2018/8071579
  2. Denosumab Related Osteonecrosis of Jaw: a Case Report vol.9, pp.4, 2018, https://doi.org/10.5037/jomr.2018.9405
  3. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review vol.27, pp.2, 2017, https://doi.org/10.1007/s00520-018-4501-x
  4. Deciphering novel chemotherapy and its impact on dentistry vol.228, pp.6, 2017, https://doi.org/10.1038/s41415-020-1365-5
  5. Imatinib-induced bone oedema mimicking Type 1 complex regional pain syndrome vol.59, pp.6, 2017, https://doi.org/10.1093/rheumatology/kez503
  6. Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors vol.8, pp.1, 2017, https://doi.org/10.1038/s41413-020-0088-1
  7. Osteonecrosis of the jaw in an anti‐resorptive naïve patient taking trastuzumab and pertuzumab: case report vol.65, pp.4, 2017, https://doi.org/10.1111/adj.12723
  8. Management of Patients under Treatment with Monoclonal Antibodies and New Biological Therapies vol.11, pp.11, 2017, https://doi.org/10.3390/app11114865
  9. Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates vol.44, pp.12, 2017, https://doi.org/10.1007/s40618-021-01634-0